Glycaemic responses to metformin monotherapy by SNP clusters in patients with type 2 diabetes
Authors' conclusion
These findings suggest that PRS derived from beta-cell dysfunction clusters may help predict glycaemic response to metformin and support the potential for genetically guided treatment in T2D.
Study context
- Population
- Individuals newly diagnosed with T2D on metformin monotherapy for 6 months, Taiwan Precision Medicine Initiative
- Exposure
- Bottom 20% of polygenic risk scores (PRS) vs top 20% of PRS for each SNP cluster
- Outcome
- Glycaemic response to metformin: changes in FBG and HbA1c
- Follow-up
- 6 months
Methodological detailsgenetic association, polygenic risk scores
- Genetic association
- Polygenic risk scores
Main finding
As reported in the abstract
Glycaemic response (FBG, HbA1c) by PRS quintile per SNP cluster
- Q1 vs Q5: P = 0.005
- Q1 vs Q5: P = 0.003
- Q1 vs Q5: P = 0.002
- Q1 vs Q5: P = 0.002
Observational data: associations, not effects.
Original publication
Glycaemic responses to metformin monotherapy by SNP clusters in patients with type 2 diabetes. Diabetes Obes Metab. Published 22 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →